Why the US right now sees psychedelics as big business

The American right once treated psychedelics as a symbol of national decline; now key figures want to fast-track them into medicine and the market.

That reversal comes with a striking family echo. In 1966, Senator Ted Kennedy pressed Timothy Leary in a Senate hearing shaped by fear, suspicion and a wider moral panic about LSD and the counterculture. Nearly 60 years later, reports indicate Robert F Kennedy Jr stood beside Donald Trump as the president signed an executive order aimed at accelerating mainstream access to medical treatments based on psychedelic drugs. The contrast captures a deeper political realignment: what the establishment once condemned as social poison now attracts support from voices inside the Maga orbit.

The shift in psychedelic politics tracks a broader truth: in America, drugs often move from moral threat to commercial opportunity when the right coalition forms around them.

The article points to ibogaine as a central example. The psychoactive compound, derived from a West African shrub, has drawn interest from scientists who suggest it may help treat chronic mental health problems. Support has also come from veterans’ lobbying, a powerful force in any US debate over trauma, treatment and public legitimacy. Add in Silicon Valley capital and media figures such as Joe Rogan, and psychedelics start to look less like a cultural taboo and more like an emerging industry with political protection.

This moment does not erase the old stigma; it repackages it. Psychedelics no longer arrive wrapped in the imagery of anti-war protest and 1960s rebellion. They now come framed as therapy, innovation and opportunity. That framing matters. It helps conservative politicians and business interests embrace substances they once treated as existential threats, while sidestepping the long history of punishment and panic that defined American drug policy.

What happens next will shape far more than one corner of healthcare. If this political momentum holds, the US could see faster regulatory movement, new investment surges and sharper fights over who profits, who gets access and whose suffering counts as urgent. Psychedelics may be entering the mainstream, but the real story lies in who controls that transition — and who cashes out when a counterculture relic becomes a sanctioned asset.